GoldenGolden
Advanced Search
Jnana Therapeutics

Jnana Therapeutics

Jnana was founded by leading academic scientists, drug developers and investors to develop medicines that transform the lives of patients.

Jnana Therapeutics is a company that was launched by top academic scientists, leaders at the forefront of chemistry, drug discovery and development, translational medicine and investors to develop medicines that transform the lives of patients.

Jnana Therapeutics is developing the first drug discovery platform that is dedicated to SLC transporters. This proprietary chemistry and biology platform enables the company to address therapeutic targets across immunometabolism, lysosomal function, and mucosal defense, where SLC transporters provide novel targets for immuno-oncology, inflammatory disorders, and neurological diseases, allowing companies to comprehensively address therapeutic targets across the vast member membrane protein family.

Jnana is dedicated to discovering and developing medicines that will make the difference for patients that are using the first drug discovery platform that is dedicated to targeting the solute carrier (SLC) family of transporters.

Timeline

August 19, 2021
Jnana Therapeutics raises a $50,000,000 series B round.
December 2017
Jnana Therapeutics raises a $50,000,000 series A round from Polaris Partners.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
FinSMEs
August 20, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Amirah Al Idrus
August 17, 2021
FierceBiotech
After years chasing a hard-to-drug group of targets called solute carriers, Jnana Therapeutics is revealing its lead program and a new $50 million financing to get it into the clinic. That program targets phenylketonuria, a rare, inherited disorder in which the amino acid phenylalanine builds up in the blood and brain.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.